Your session is about to expire
← Back to Search
Procedure
TMS + Exposure Therapy for Pediatric OCD (NExT Trial)
N/A
Recruiting
Led By Christine Conelea, PhD
Research Sponsored by Bradley Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up two weeks
Awards & highlights
No Placebo-Only Group
Summary
This trial tests whether combining TMS with ERP therapy can help young people with OCD better manage their compulsions. TMS uses magnetic fields to stimulate brain areas linked to compulsive behavior. The study will compare different types of TMS to see which works best. Repetitive transcranial magnetic stimulation (rTMS) has been widely used as a therapy for severe obsessive-compulsive disorder (OCD).
Who is the study for?
This trial is for young people aged 12-21 with moderate to severe OCD, as shown by specific test scores. They must speak English and have motor compulsions. It's not for left-handed individuals, those on certain medications or with conditions that increase TMS risks (like epilepsy), pregnant girls not using contraception, anyone unable to undergo MRI, or if they've had psychosis, recent substance abuse, other OCD therapies or TMS treatments recently.
What is being tested?
The study tests how different types of transcranial magnetic stimulation (TMS) can help improve Exposure with Response Prevention therapy in treating OCD. Participants will receive either active TMS targeting specific brain areas or sham TMS alongside their therapy over two weeks and will be assessed through interviews, questionnaires, tasks and MRIs.
What are the potential side effects?
TMS may cause discomfort at the stimulation site, headache, lightheadedness or seizures in rare cases. The risk of side effects varies based on individual health profiles and the specifics of the TMS procedure.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ change from baseline at two weeks (post-treatment)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline at two weeks (post-treatment)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Functional Magnetic Resonance Imaging (fMRI): connectivity of the dlPFC-DMS circuit
Functional Magnetic Resonance Imaging (fMRI): connectivity of the pSMA-DLS circuit
Observed Compulsive Behavior
Secondary study objectives
Child/Adult Yale-Brown Obsessive Compulsive Inventory
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: ERP+iTBSExperimental Treatment2 Interventions
Participants will receive two weeks (10 sessions) of intermittent theta burst stimulation (iTBS; a form of TMS) targeting the dorsolateral prefrontal cortex (dlPFC), followed immediately by Exposure Plus Response Prevention (ERP).
Group II: ERP+cTBSExperimental Treatment2 Interventions
Participants will receive two weeks (10 sessions) of continuous theta burst stimulation (cTBS; a form of TMS) targeting the presupplementary motor area (pSMA), followed immediately by Exposure Plus Response Prevention (ERP).
Group III: ERP+ShamActive Control2 Interventions
Participants will receive two weeks (10 sessions) of sham ("fake") TMS, followed immediately by Exposure Plus Response Prevention (ERP).
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Obsessive-Compulsive Disorder (OCD) include neuromodulation techniques like Transcranial Magnetic Stimulation (TMS) and pharmacological treatments such as selective serotonin reuptake inhibitors (SSRIs). TMS works by modulating neural activity in brain circuits associated with compulsive behavior, directly targeting the dysfunctional areas involved in OCD.
SSRIs increase serotonin levels in the brain, which helps to reduce OCD symptoms by improving mood and reducing anxiety. These treatments are crucial for OCD patients as they aim to correct the underlying neural imbalances, offering potential relief from compulsions and improving quality of life.
[Repetitive transcranial magnetic stimulation in the treatment of obsessive-compulsive disorder].
[Repetitive transcranial magnetic stimulation in the treatment of obsessive-compulsive disorder].
Find a Location
Who is running the clinical trial?
Bradley HospitalLead Sponsor
17 Previous Clinical Trials
1,501 Total Patients Enrolled
3 Trials studying Obsessive-Compulsive Disorder
563 Patients Enrolled for Obsessive-Compulsive Disorder
University of MinnesotaOTHER
1,433 Previous Clinical Trials
1,621,266 Total Patients Enrolled
5 Trials studying Obsessive-Compulsive Disorder
125 Patients Enrolled for Obsessive-Compulsive Disorder
Butler HospitalOTHER
131 Previous Clinical Trials
16,448 Total Patients Enrolled
12 Trials studying Obsessive-Compulsive Disorder
387 Patients Enrolled for Obsessive-Compulsive Disorder
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am pregnant or not using effective birth control and am sexually active.My medication dose has been stable for the last 6 weeks with no changes expected.I am between 12 and 21 years old.I have moderate or severe OCD based on a specific test score.I am currently receiving therapy for OCD.I have not had TMS treatment in the last 3 months.I am on medication that my doctor says could increase my risk of seizures.
Research Study Groups:
This trial has the following groups:- Group 1: ERP+iTBS
- Group 2: ERP+cTBS
- Group 3: ERP+Sham
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger